Publications

Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M, Meyer J, Habel A, Eisel J, Poschet G, Weller M, Preusser M, Nadji-Ohl M, Thon N, Burger MC, Harter PN, Ratliff M, Harbottle R, Benner A, Schrimpf D, Okun J, Herold-Mende C, Turcan S, Kaulfuss S, Hess-Stumpp H, Bieback K, Cahill DP, Plate KH, Hänggi D, Dorsch M, Suvà ML, Niemeyer BA, von Deimling A, Wick W, Platten M.

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.

Nat Med. 2018 Aug;24(8):1192-1203

https://www.ncbi.nlm.nih.gov/pubmed/29988124

Platten M, Schilling D, Bunse L, Wick A, Bunse T, Riehl D, Karapanagiotou-Schenkel I, Harting I, Sahm F, Schmitt A, Steinbach J, Weyerbrock A, Hense J, Misch M, Krex D, Stevanović S, Tabatabai G, von Deimling A, Schmitt M, Wick W (2018).

A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).

Oral presentation at the Annual ASCO Conference 2018

https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.2001

Buhl JL, Selt F, Hielscher T, Guiho R, Ecker J, Sahm F, Ridinger J, Riehl D, Usta D, Ismer B, Sommerkamp AC, Martinez-Babera JP, Wefers AK, Remke M, Picard D, Pusch S, Gronych J, Oehme I, van Tilburg CM, Kool M, Kuhn D, Capper D, von Deimling A, Schuhmann M, Herold-Mende C, Korshunov A, Brummer T, Pfister SM, Jones DTW, Witt O, Milde T.

The senescence-associated secretory phenotype mediates oncogene-induced senescence in pediatric pilocytic astrocytoma.

Clin Cancer Res. 2018 Dec 7.

https://www.ncbi.nlm.nih.gov/pubmed/30530705

Wabnitz GH, Kirchgessner H, Jahraus B, Umansky L, Shenolikar S, Samstag Y.

Protein Phosphatase 1αand Cofilin Regulate Nuclear Translocation of NF-κB and Promote Expression of the Anti-Inflammatory Cytokine Interleukin-10 by T Cells.

Mol Cell Biol. 2018 Oct 29;38(22).

https://www.ncbi.nlm.nih.gov/pubmed/30181394

Yamauchi Y, Safi S, Blattner C, Rathinasamy A, Umansky L, Juenger S, Warth A, Eichhorn M, Muley T, Herth FJF, Dienemann H, Platten M, Beckhove P, Utikal J, Hoffmann H, Umansky V.

Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer.

Am J Respir Crit Care Med. 2018 Sep 15;198(6):777-787

https://www.ncbi.nlm.nih.gov/pubmed/29617574

Platten M, Bunse L, Riehl D, Bunse T, Ochs K, Wick W.

Vaccine Strategies in Gliomas.

Curr Treat Options Neurol. 2018 Mar 28;20(5):11.

https://www.ncbi.nlm.nih.gov/pubmed/29594595

Haag GM, Zoernig I, Hassel JC, Halama N, Dick J, Lang N, Podola L, Funk J, Ziegelmeier C, Juenger S, Bucur M, Umansky L, Falk CS, Freitag A, Karapanagiotou-Schenkel I, Beckhove P, Enk A, Jaeger D.

Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1. Eur J Cancer. 2018 Feb;90:122-129

https://www.ncbi.nlm.nih.gov/pubmed/29306769

Schmitz-Winnenthal FH, Hohmann N, Schmidt T, Podola L, Friedrich T, Lubenau H, Springer M, Wieckowski S, Breiner KM, Mikus G, Büchler MW, Keller AV, Koc R, Springfeld C, Knebel P, Bucur M, Grenacher L, Haefeli WE, Beckhove P.

A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.

Oncoimmunology. 2018 Jan 16;7(4)

https://www.ncbi.nlm.nih.gov/pubmed/29632710

 

Rapp C, Warta R, Stamova S, Nowrouzi A, Geisenberger C, Gal Z, Roesch S, Dettling S, Juenger S, Bucur M, Jungk C, DaoTrong P, Ahmadi R, Sahm F, Reuss D, Fermi V, Herpel E, Eckstein V, Grabe N, Schramm C, Weigand MA, Debus J, von Deimling A, Unterberg A, Abdollahi A, Beckhove P, Herold-Mende C.

Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens.

Acta Neuropathol. 2017 Aug;134(2):297-316

https://www.ncbi.nlm.nih.gov/pubmed/28332095

Rathinasamy A, Domschke C, Ge Y, Böhm HH, Dettling S, Jansen D, Lasitschka F, Umansky L, Gräler MH, Hartmann J, Herold-Mende C, Schuetz F, Beckhove P.

Tumor specific regulatory T cells in the bone marrow of breast cancer patients selectively upregulate the emigration receptor S1P1.

Cancer Immunol Immunother. 2017 May;66(5):593-603.

https://www.ncbi.nlm.nih.gov/pubmed/28224210

Ochs K, Ott M, Bunse T, Sahm F, Bunse L, Deumelandt K, Sonner JK, Keil M, von Deimling A, Wick W, Platten M. K27M-mutant histone-3 as a novel target for glioma immunotherapy.

Oncoimmunology. 2017 May 12;6(7)

https://www.ncbi.nlm.nih.gov/pubmed/28811969

Wiskemann J., Hummler S., Diepold C., Keil M., Abel U., Steindorf K., Beckhove P., Ulrich C.M., Steins M. and Thomas M.;

POSITIVE study: physical exercise program in non-operable lung cancer patients undergoing palliative treatment.

BMC Cancer. 2016 Jul 16:499 DOI: 10.1186/s12885-016-2561-1

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949758/

Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K, Holland-Letz, T., Umansky L, Beckhove P, Sucker A, Schadendorf D, Utikal J, Umansky V.

Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab.

Clin. Cancer Res., 2015, DOI:10.158/1078-0432.CCR-15-0676.

https://www.ncbi.nlm.nih.gov/pubmed/26289067

Schneider T, Sevko A, Heussel CP, Umansky L, Beckhove P, Dienemann H, Safi S, Utikal J, Hoffmann H, Umansky V.

Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small cell lung cancer.

Clin Exp Immunol. 2015, 180:467-474.

https://www.ncbi.nlm.nih.gov/pubmed/25644608

Schmitz-Winnenthal FH, Hohmann N, Niethammer AG, Friedrich T, Lubenau H, Springer M, Breiner KM, Mikus G, Weitz J, Ulrich A, Buechler MW, Pianka F, Klaiber U, Diener M, Leowardi C, Schimmack S, Sisic L, Keller AV, Koc R, Springfeld C, Knebel P, Schmidt T, Ge Y, Bucur M, Stamova S, Podola L, Haefeli WE, Grenacher L, Beckhove P.

Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.

Oncoimmunology. 2015 Mar 16;4(4):1001217. eCollection 2015 Apr.

https://www.ncbi.nlm.nih.gov/pubmed/26137397

Domschke C., Ge Y., Bernahrd I., Schott S., Keim S., Juenger S., Bucur M., Mayer L., Blumenstein M., Rom J., Heil J., Sohn C., Schneeweiss A., Beckhove P., Schetz F.,

Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized brest cancer: follow-up analysis of clinical pilot trial.

Cancer Immunol Immunother. 2013 Jun;62(6):1053-60. Doi: 10.1007/s00262-013-1414-x Epub 2013 Apr 18.

https://www.ncbi.nlm.nih.gov/pubmed/23595207

to top